A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HOWL SEC filings page.
This page shows Werewolf Therapeutics, Inc. (HOWL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
By FY2025, this development-stage business had shrinking resources, heavier leverage, and operating cash use nearly equal to reported losses.
Assets fell45.3% from FY2024 to FY2025, but liabilities declined only16.7% . That mismatch pushed liabilities to64.3% of assets from42.2% , showing creditors represented a larger claim as the resource base contracted.
The FY2025 net loss was
R&D was
Financial Health Signals
We are recalculating Werewolf Therapeutics, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Werewolf Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Werewolf Therapeutics, Inc. reported a net loss of $60.8M while operations used $60.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Werewolf Therapeutics, Inc. reported an operating loss of $60.7M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Werewolf Therapeutics, Inc.'s EBITDA was -$8.8M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 191.5%.
Werewolf Therapeutics, Inc. reported a net loss of $9.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 369.1%.
Werewolf Therapeutics, Inc. earned -$0.20 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 350.0%.
Not reported for Q3 2026.
Cash & Balance Sheet
Werewolf Therapeutics, Inc. held $41.9M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Werewolf Therapeutics, Inc.'s quarterly ROE was -146.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 90.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 168.7 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Werewolf Therapeutics, Inc. invested $2.2M in research and development in Q3 2026. This represents a decrease of 81.3% from the same quarter a year earlier. Against the prior quarter it is down 64.7%.
Not reported for Q3 2026.
Not reported for Q3 2026.
HOWL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4/A |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $2.2M-81.3% | $6.2M-53.1% | $8.2M-37.6% | $6.9M-55.9% | $11.6M-7.1% | $13.1M-13.9% | $13.1M+1.6% | $15.7M+63.0% |
| SG&A Expenses | $7.9M+92.5% | $7.7M+74.6% | $5.1M+4.5% | $2.5M-46.2% | $4.1M-11.0% | $4.4M-9.0% | $4.9M-2.5% | $4.6M-4.0% |
| Operating Income | -$10.1Mn/m | $7.2Mn/m | -$13.3Mn/m | -$9.4Mn/m | -$15.7Mn/m | -$17.5Mn/m | -$18.0Mn/m | -$20.3Mn/m |
| EBITDA | -$8.8Mn/m | $9.6Mn/m | -$12.9Mn/m | -$9.0Mn/m | -$15.3Mn/m | -$17.1Mn/m | -$17.6Mn/m | -$19.9Mn/m |
| Interest Expense | $0-100.0% | $475K-63.5% | $1.4M+8.3% | N/A | $1.3M+7.8% | $1.3M+62.6% | $1.3Mn/m | N/A |
| Net Income | -$9.9Mn/m | $3.7Mn/m | -$13.5Mn/m | -$8.4Mn/m | -$16.4Mn/m | -$18.0Mn/m | -$18.1Mn/m | -$20.4Mn/m |
| EPS (Basic) | -$0.20n/m | $0.08n/m | -$0.28n/m | -$0.16n/m | -$0.36n/m | -$0.40n/m | -$0.40n/m | -$0.46n/m |
| EPS (Diluted) | -$0.20n/m | $0.08n/m | -$0.28n/m | -$0.17n/m | -$0.36n/m | -$0.40n/m | -$0.40n/m | -$0.44n/m |
| Diluted Shares (Avg) | 49M+6.1% | 49M+8.0% | 49M+10.2% | N/A | 46M+4.8% | 45M+2.1% | 45M+7.7% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
HOWL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $42.8M-46.3% | $24.2M-73.9% | $58.0M-45.9% | $69.4M-45.3% | $79.6M-43.1% | $92.6M-39.8% | $107.2M-39.6% | $126.9M-27.4% |
| Current Assets | $42.8M-37.3% | $22.9M-71.5% | $48.7M-48.4% | $58.6M-48.2% | $68.2M-45.8% | $80.4M-42.0% | $94.5M-33.6% | $113.1M-18.3% |
| Cash & Equivalents | $41.9M-36.3% | $22.0M-71.7% | $46.5M-49.5% | $57.0M-48.6% | $65.7M-46.5% | $77.6M-42.7% | $92.0M-33.9% | $111.0M-17.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $36.0M-28.0% | $7.9M-84.6% | $45.8M-8.2% | $44.6M-16.7% | $50.0M-1.3% | $51.1M+2.9% | $49.9M-16.8% | $53.5M-15.6% |
| Current Liabilities | $36.0M+104.5% | $7.9M-48.2% | $38.5M+230.1% | $36.1M+138.1% | $17.6M+41.2% | $15.2M+32.6% | $11.7M-45.0% | $15.2M-21.7% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $7.3M-80.9% | $8.4M-78.0% | $32.4M-15.1% | $35.9M-6.0% | $38.3M-1.4% | $38.4M-13.0% |
| Long-Term Debt | N/A | N/A | $32.1M0.0% | $32.1M0.0% | $32.1M0.0% | $32.1M0.0% | $32.1M-19.8% | $32.1M-19.8% |
| Total Equity | $6.8M-77.2% | $16.3M-60.7% | $12.2M-78.7% | $24.8M-66.2% | $29.6M-66.9% | $41.5M-60.1% | $57.3M-51.3% | $73.4M-34.1% |
| Retained Earnings | -$495.1Mn/m | -$485.3Mn/m | -$488.9Mn/m | -$475.4Mn/m | -$467.0Mn/m | -$450.7Mn/m | -$432.7Mn/m | -$414.6Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
HOWL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4/A |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.0Mn/m | $6.6Mn/m | -$10.6Mn/m | -$11.0Mn/m | -$15.2Mn/m | -$15.2Mn/m | -$18.9Mn/m | -$14.3Mn/m |
| Depreciation & Amortization | $1.3M+214.2% | $2.5M+503.9% | $398K-6.6% | $400K-9.5% | $402K-11.5% | $406K-10.6% | $426K-8.2% | $442K-3.9% |
| Stock-Based Compensation | $344K-72.1% | $419K-76.6% | $929K-53.7% | N/A | $1.2M-38.7% | $1.8M-31.1% | $2.0M-13.0% | N/A |
| Capital Expenditures | N/A | N/A | N/A | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $123K-37.9% |
| Free Cash Flow | N/A | N/A | N/A | -$11.0Mn/m | -$15.2Mn/m | -$15.2Mn/m | -$18.9Mn/m | -$14.4Mn/m |
| Investing Cash Flow | $28.9Mn/m | N/A | N/A | $0n/m | $0n/m | $0n/m | $0n/m | -$123Kn/m |
| Financing Cash Flow | $0-100.0% | N/A | N/A | $2.4M-7.1% | $3.3Mn/m | $388Kn/m | $0-100.0% | $2.5M-71.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
HOWL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4/A |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -146.1%-90.9pp | 22.5%+65.9pp | -110.9%-79.3pp | -33.8%-6.0pp | -55.3%-36.6pp | -43.4%-26.8pp | -31.6%-17.8pp | -27.8%-17.0pp |
| Return on Assets | -23.1%-2.5pp | 15.2%+34.6pp | -23.3%-6.5pp | -12.1%+4.0pp | -20.6%-8.7pp | -19.4%-8.2pp | -16.9%-7.7pp | -16.1%-9.2pp |
| Current Ratio | 1.19-2.7x | 2.91-2.4x | 1.27-6.8x | 1.62-5.8x | 3.87-6.2x | 5.30-6.8x | 8.09+1.4x | 7.45+0.3x |
| Debt-to-Equity | N/A | N/A | 2.63+2.1x | 1.29+0.9x | 1.08+0.7x | 0.77+0.5x | 0.56+0.2x | 0.44+0.1x |
| Liabilities-to-Equity | 5.33+3.6x | 0.48-0.7x | 3.76+2.9x | 1.80+1.1x | 1.69+1.1x | 1.23+0.8x | 0.87+0.4x | 0.73+0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. HOWL | FY2025 | N/A | -$60.8M | N/A | $50.1M | — |
| Pliant Therapeutics, Inc. PLRX | FY2025 | $0 | -$149.3M | N/A | $41.0M | — |
| MiNK Therapeutics, Inc. INKT | FY2025 | N/A | -$12.5M | N/A | $45.4M | — |
| Rein Therapeutics, Inc. RNTX | FY2025 | $0 | -$49.9M | N/A | $30.7M | — |
| Gain Therapeutics, Inc. GANX | FY2025 | N/A | -$20.2M | N/A | $49.4M | — |
| Oncolytics Biotech, Inc. ONCY | FY2025 | N/A | -$28.8M | N/A | $59.9M | — |
Where Werewolf Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Werewolf Therapeutics, Inc. (HOWL) reported a net loss of $60.8M in fiscal year 2025.
Werewolf Therapeutics, Inc. (HOWL) had EBITDA of -$59.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Werewolf Therapeutics, Inc. (HOWL) had $57.0M in cash and equivalents against $32.1M in long-term debt.
Werewolf Therapeutics, Inc. (HOWL) has a return on equity of -245.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Werewolf Therapeutics, Inc. (HOWL) recorded an outflow of $60.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Werewolf Therapeutics, Inc. (HOWL) recorded an outflow of $60.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Werewolf Therapeutics, Inc. (HOWL) had $69.4M in total assets as of fiscal year 2025, including both current and long-term assets.
Werewolf Therapeutics, Inc. (HOWL) reported no capital expenditure during fiscal year 2025.
Werewolf Therapeutics, Inc. (HOWL) invested $44.8M in research and development during fiscal year 2025.
Werewolf Therapeutics, Inc. (HOWL) had a current ratio of 1.62 as of fiscal year 2025, which is generally considered healthy.
Werewolf Therapeutics, Inc. (HOWL) had a debt-to-equity ratio of 1.29 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Werewolf Therapeutics, Inc. (HOWL) had a liabilities-to-equity ratio of 1.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Werewolf Therapeutics, Inc. (HOWL) had a return on assets of -87.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Werewolf Therapeutics, Inc. (HOWL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $50.1M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Werewolf Therapeutics, Inc. (HOWL) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $50.1M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Werewolf Therapeutics, Inc. (HOWL) held $57.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $60.3M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Werewolf Therapeutics, Inc. (HOWL) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Werewolf Therapeutics, Inc. (HOWL) reported a net loss of $60.8M while operations used $60.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Werewolf Therapeutics, Inc. (HOWL) reported an operating loss of $60.7M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.